For more than 20 years, hormone therapy for menopause has carried a warning label from the Food and Drug Administration describing the medication’s risk of serious harms – namely, cancer, cardiovascular disease and possibly dementia.
On Nov. 10, 2025, the FDA announced that drugmakers should remove these “black box” safety warnings.
The Conversation U.S. asked Genevieve Hofmann, a women’s health nurse practitioner at the University of Colorado Anschutz, to explain how the decision will affect health care for people going through menopause or postmenopause.